Abstract
The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10605-10616 |
| Number of pages | 12 |
| Journal | Journal of Virology |
| Volume | 85 |
| Issue number | 20 |
| DOIs | |
| State | Published - Oct 2011 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Virology
Cite this
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. / Blaney, Joseph E.; Wirblich, Christoph; Papaneri, Amy B.; Johnson, Reed F.; Myers, Carey J.; Juelich, Terry L.; Holbrook, Michael R.; Freiberg, Alexander; Bernbaum, John G.; Jahrling, Peter B.; Paragas, Jason; Schnell, Matthias J.
In: Journal of Virology, Vol. 85, No. 20, 10.2011, p. 10605-10616.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses
AU - Blaney, Joseph E.
AU - Wirblich, Christoph
AU - Papaneri, Amy B.
AU - Johnson, Reed F.
AU - Myers, Carey J.
AU - Juelich, Terry L.
AU - Holbrook, Michael R.
AU - Freiberg, Alexander
AU - Bernbaum, John G.
AU - Jahrling, Peter B.
AU - Paragas, Jason
AU - Schnell, Matthias J.
PY - 2011/10
Y1 - 2011/10
N2 - The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.
AB - The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.
UR - http://www.scopus.com/inward/record.url?scp=80055058700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80055058700&partnerID=8YFLogxK
U2 - 10.1128/JVI.00558-11
DO - 10.1128/JVI.00558-11
M3 - Article
VL - 85
SP - 10605
EP - 10616
JO - Journal of Virology
JF - Journal of Virology
SN - 0022-538X
IS - 20
ER -